FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1479754183> ?p ?o ?g. }

• W1479754183 abstract "Melanoma represents only 4% of all skin cancers, yet its prognosis is especially grim once the metastatic disease state has been reached. However, the genotype of melanomas may provide an opportunity for therapeutic intervention. For example, 90% of cases retain wild-type p53 and a considerable number of these present deletions in the chromosome region that encodes interferon-beta; (IFN). In our previous work, we developed adenoviral vectors where transgene expression is controlled by p53 and propose that such vectors would be especially interesting for the treatment of melanoma. We have used these vectors to transfer the mouse IFN cDNA in murine models, including melanoma, and have observed a significant ability of IFN to inhibit cell proliferation in vitro and in vivo (Merkel et al, 2013). In addition, we have shown that the application of IFN contributes to an anti-tumor immune response (unpublished data). Here we present our recent efforts to adapt this strategy to a model of human melanoma. To this end, the human IFN cDNA was cloned into an adenoviral vector that offers CAR-independent transduction due to the incorporation of the RGD tripeptide in the fiber as well as expression of the transgene under the control of p53. We expect that the AdRGDPGhIbeta; vector will provide expression of human IFN in response to cellular p53 activity. Reliable vector expression was confirmed by ELISA. Then SK-MEL-05 and SK-MEL-147 (human melanoma cell lines harboring wild-type p53) were transduced, incubated for 48, 72 or 96 hours of incubation and then cell cycle alterations were assessed by PI/FACS analysis. We observed a time-dependent accumulation of hypodiploid cells in either cell line when treated with the AdRGDPGhIbeta; vector, yet non-treated or treatment with a GFP-expressing virus did not alter the cell cycle profile. At the final time point, more than 90% of cells treated with IFN were hypodiploid. This result suggests that endogenous p53 reliably induced vector expression and that IFN was an efficient inducer of cell death. We observed the paracrine effects of this treatment when we mixed non-transduced cells with transduced cells and obtained a dose-dependent accumulation of hypodiploid cells. In this assay, the presence of only 5% transduced cells was sufficient to kill 40% of the total cell population in both the SK-MEL-05 and SK-MEL-147 cell lines. We are especially encouraged by these results since our mouse models using Ad5 to transfer murine IFN were less efficient in inducing cell death than seen in the human model. At this time we are determining the mechanism of cell death as well as initiating a model of in situ gene therapy with human IFN. Grants #2010/15025-0 and 2013/25167-5, Sao Paulo Research Foundation (FAPESP). Citation Format: Taynah David, Bryan Eric Strauss. Interferon-beta gene transfer to human melanoma cell lines using a specialized adenoviral vector induces high levels of cell death. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Melanoma: From Biology to Therapy; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(14 Suppl):Abstract nr B37." @default.
• W1479754183 created "2016-06-24" @default.
• W1479754183 creator A5061597116 @default.
• W1479754183 creator A5090759092 @default.
• W1479754183 date "2015-07-15" @default.
• W1479754183 modified "2023-09-22" @default.
• W1479754183 title "Abstract B37: Interferon-beta gene transfer to human melanoma cell lines using a specialized adenoviral vector induces high levels of cell death" @default.
• W1479754183 doi "https://doi.org/10.1158/1538-7445.mel2014-b37" @default.
• W1479754183 hasPublicationYear "2015" @default.
• W1479754183 type Work @default.
• W1479754183 sameAs 1479754183 @default.
• W1479754183 citedByCount "0" @default.
• W1479754183 crossrefType "proceedings-article" @default.
• W1479754183 hasAuthorship W1479754183A5061597116 @default.
• W1479754183 hasAuthorship W1479754183A5090759092 @default.
• W1479754183 hasConcept C102230213 @default.
• W1479754183 hasConcept C104317684 @default.
• W1479754183 hasConcept C111599444 @default.
• W1479754183 hasConcept C15152581 @default.
• W1479754183 hasConcept C203014093 @default.
• W1479754183 hasConcept C2776178377 @default.
• W1479754183 hasConcept C2777658100 @default.
• W1479754183 hasConcept C32470452 @default.
• W1479754183 hasConcept C40767141 @default.
• W1479754183 hasConcept C502942594 @default.
• W1479754183 hasConcept C54355233 @default.
• W1479754183 hasConcept C55493867 @default.
• W1479754183 hasConcept C81885089 @default.
• W1479754183 hasConcept C86803240 @default.
• W1479754183 hasConceptScore W1479754183C102230213 @default.
• W1479754183 hasConceptScore W1479754183C104317684 @default.
• W1479754183 hasConceptScore W1479754183C111599444 @default.
• W1479754183 hasConceptScore W1479754183C15152581 @default.
• W1479754183 hasConceptScore W1479754183C203014093 @default.
• W1479754183 hasConceptScore W1479754183C2776178377 @default.
• W1479754183 hasConceptScore W1479754183C2777658100 @default.
• W1479754183 hasConceptScore W1479754183C32470452 @default.
• W1479754183 hasConceptScore W1479754183C40767141 @default.
• W1479754183 hasConceptScore W1479754183C502942594 @default.
• W1479754183 hasConceptScore W1479754183C54355233 @default.
• W1479754183 hasConceptScore W1479754183C55493867 @default.
• W1479754183 hasConceptScore W1479754183C81885089 @default.
• W1479754183 hasConceptScore W1479754183C86803240 @default.
• W1479754183 hasLocation W14797541831 @default.
• W1479754183 hasOpenAccess W1479754183 @default.
• W1479754183 hasPrimaryLocation W14797541831 @default.
• W1479754183 hasRelatedWork W1971203644 @default.
• W1479754183 hasRelatedWork W1974613901 @default.
• W1479754183 hasRelatedWork W1999521430 @default.
• W1479754183 hasRelatedWork W2002162999 @default.
• W1479754183 hasRelatedWork W2022761871 @default.
• W1479754183 hasRelatedWork W2036045557 @default.
• W1479754183 hasRelatedWork W2042023457 @default.
• W1479754183 hasRelatedWork W2139490292 @default.
• W1479754183 hasRelatedWork W2180993978 @default.
• W1479754183 hasRelatedWork W2315289350 @default.
• W1479754183 hasRelatedWork W2321756929 @default.
• W1479754183 hasRelatedWork W2472498290 @default.
• W1479754183 hasRelatedWork W2478929778 @default.
• W1479754183 hasRelatedWork W2523401122 @default.
• W1479754183 hasRelatedWork W2562108327 @default.
• W1479754183 hasRelatedWork W2564542754 @default.
• W1479754183 hasRelatedWork W2944431247 @default.
• W1479754183 hasRelatedWork W2994938762 @default.
• W1479754183 hasRelatedWork W3094039092 @default.
• W1479754183 hasRelatedWork W3158074931 @default.
• W1479754183 isParatext "false" @default.
• W1479754183 isRetracted "false" @default.
• W1479754183 magId "1479754183" @default.
• W1479754183 workType "article" @default.